Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Therapy-related core binding factor Acute Myeloid Leukemia – a Study of the french acute leukemia intergroup

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMathilde ChanutUniversité de Versailles Saint-Quentin-en-YvelinesTBThorsten BraunHumboldt-Universität zu BerlinMUMadalina UzunovSorbonne Université

Discussion

Loading...

Member takes

Implication

Retrospective analysis reveals similar outcomes in therapy-related versus de novo acute myeloid leukemia patients, suggesting treatment efficacy.

Key Points

  • To investigate the characteristics and outcomes of therapy-related CBF-AML compared to de novo cases.
  • Retrospective multicenter analysis of CBF-AML patients
  • Inclusion of patient data from the French AML intergroup
  • Comparison of outcomes and characteristics between t-AML and de novo cases
  • Among 749 patients, 78 had t-AML, showing older age and lower WBC counts at diagnosis
  • No difference in CR/CRp rates, relapse incidence, or non-relapse mortality between t-AML and de novo patients
  • Overall survival was similar after multivariable adjustment for age and WBC count

Cite This Study

Chanut et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e5https://doi.org/10.1182/blood-2025-37
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy2024 · 12 citations
  2. 2Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.2024
  3. 3Therapy-related AML (t-AML) on the rise: A national perspective on evolving trends, treatment outcomes, and prognostic implications in hospitalized patients2025
  4. 4Differential Prognosis and Transplant Strategies in <scp>CBF</scp> ‐ <scp>AML</scp> With <i> <scp>RUNX1</scp> :: <scp>RUNX1T1</scp> </i> Versus <i> <scp>CBFβ</scp> :: <scp>MYH11</scp> </i> Fusions2026 · 2 citations
  5. 5Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial2025